singapore-asia-pacific-neurodegeneration

Migration, Crosslink

📖

singapore-asia-pacific-neurodegeneration

active

wiki page Created: 2026-04-02T07:20:07 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-singapore-asia-pacific-ne

📖 Wiki Page

company2736 wordssynced 2026-04-02

Singapore and Asia-Pacific Neurodegeneration Biotech Companies

Overview

flowchart TD companies_singapore_asia_pacif["singapore-asia-pacific-neurodegeneration"] style companies_singapore_asia_pacif fill:#4fc3f7,stroke:#333,color:#000 companies_singapore__0["Singapore Biotechnology Ecosystem"] companies_singapore_asia_pacif -->|"includes"| companies_singapore__0 style companies_singapore__0 fill:#81c784,stroke:#333,color:#000 companies_singapore__1["Government Support and Infrastructure"] companies_singapore_asia_pacif -->|"includes"| companies_singapore__1 style companies_singapore__1 fill:#ef5350,stroke:#333,color:#000 companies_singapore__2["Biopolis and Research Parks"] companies_singapore_asia_pacif -->|"includes"| companies_singapore__2 style companies_singapore__2 fill:#ffd54f,stroke:#333,color:#000 companies_singapore__3["Singapore-Based Companies"] companies_singapore_asia_pacif -->|"includes"| companies_singapore__3 style companies_singapore__3 fill:#ce93d8,stroke:#333,color:#000 companies_singapore__4["Trevari Pte Ltd"] companies_singapore_asia_pacif -->|"includes"| companies_singapore__4 style companies_singapore__4 fill:#4fc3f7,stroke:#333,color:#000 companies_singapore__5["Cognizance Neurotherapeutics"] companies_singapore_asia_pacif -->|"includes"| companies_singapore__5 style companies_singapore__5 fill:#81c784,stroke:#333,color:#000

...

Singapore and Asia-Pacific Neurodegeneration Biotech Companies

Overview

Mermaid diagram (expand to render)

The Asia-Pacific region has emerged as a dynamic hub for biotechnology innovation, with Singapore serving as the premier destination for neuroscience research and drug development in the region. The rapid growth of neurodegenerative disease biotech companies across Singapore, Australia, Taiwan, Japan, and South Korea reflects both the substantial unmet medical need and the region's growing scientific capabilities["@biotech_hubs"][@biotech_investment].

Singapore, in particular, has positioned itself as "Asia's biotech hub" through strategic government investment, world-class research infrastructure, and proactive policies that encourage pharmaceutical R&D. The nation hosts over 300 biotech companies, with a significant focus on CNS disorders. This ecosystem has been built through coordinated efforts between the Agency for Science, Technology and Research (A*STAR), the National University of Singapore (NUS), and the Economic Development Board (EDB), creating a seamless pipeline from basic research to commercial development["astar"][@neuroscience_singapore].

The Asia-Pacific neurodegenerative disease market represents a substantial opportunity, with over 30 million people affected by Alzheimer's disease and Parkinson's disease across the region. The demographic transition toward aging populations in Japan, South Korea, China, and Singapore ensures that this burden will continue to grow, driving demand for novel therapeutics["alzheimer_asia"].

Singapore Biotechnology Ecosystem

Government Support and Infrastructure

Singapore's biotechnology sector benefits from comprehensive government support:

A*STAR (Agency for Science, Technology and Research)

A*STAR serves as the primary driver of public sector research, operating multiple research institutes focused on neuroscience and drug discovery:

Institute of Molecular and Cell Biology (IMCB): Focus on cellular and molecular neuroscience
Biology Resource Centre: Provides animal models for neurodegenerative disease research
Computational Resource Centre: Supports AI-driven drug discovery initiatives
Singapore Bioimaging Consortium: Advanced neuroimaging capabilities

The Agency coordinates with universities and hospitals to translate basic research into therapeutic candidates, maintaining a robust pipeline of early-stage programs[astar][@neuroscience_singapore].

National Research Foundation (NRF)

The NRF provides funding for strategic research initiatives, including:

Translational and Clinical Research Flagship Programs: Dedicated funding for neurodegenerative disease research
Competitive Research Programmes: Investigator-initiated grants for neuroscience
Singapore Translational Research (StaR) Awards: Support for distinguished investigators

Economic Development Board (EDB)

The EDB attracts international pharmaceutical companies and supports local biotech development through:

Tax incentives: Tax holidays and enhanced deductions for R&D spending
Infrastructure support: Biopolis and other dedicated research facilities
Talent development: Programs to attract and train scientific workforce

Biopolis and Research Parks

The Biopolis in Singapore represents a flagship research campus housing:

Public research institutes: A*STAR research centers
International pharma labs: Novartis, Pfizer, Roche, GlaxoSmithKline
Local biotech companies: numerous startups and emerging companies
Academic research centers: NUS and Nanyang Technological University (NTU) satellite labs

This concentrated ecosystem facilitates collaboration, knowledge sharing, and talent mobility, accelerating the drug discovery process[biotech_hubs].

Singapore-Based Companies

Trevari Pte Ltd

Focus: Alzheimer's disease therapeutics

Founded: 2018

Headquarters: Singapore

Approach: Trevari represents Singapore's focus on innovative Alzheimer's disease therapies. The company's pipeline includes novel small molecule inhibitors targeting multiple aspects of Alzheimer's disease pathology.

Pipeline

| Product | Mechanism | Indication | Stage |
|---------|-----------|------------|-------|
| TRV-101 | Beta-secretase (BACE) inhibitor | Alzheimer's disease | Preclinical |
| TRV-102 | Tau aggregation inhibitor | Alzheimer's disease | Discovery |
| TRV-103 | Synaptic preservation modulator | Alzheimer's disease | Research |

BACE Inhibition Strategy

TRV-101 targets beta-secretase (BACE), the enzyme responsible for amyloid-beta production. BACE cleavage of amyloid precursor protein (APP) represents the rate-limiting step in amyloid-beta generation, making this a high-priority therapeutic target[@bace_inhibitors].

Key considerations for BACE inhibitor development include:

Safety: BACE plays roles in synaptic function, requiring careful safety margin
Brain penetration: Achieving adequate CNS exposure
Selectivity: Avoiding off-target effects on related proteases
Efficacy: Demonstrating amyloid reduction in humans

Tau Aggregation Inhibition

TRV-102 targets tau protein aggregation, which correlates strongly with cognitive decline in Alzheimer's disease. The spread of tau pathology through connected brain regions follows a predictable pattern that mirrors clinical progression[@tau_pathology].

Cognizance Neurotherapeutics

Focus: Neuroprotection for Alzheimer's and Parkinson's disease

Stage: Research

Approach: Cognizance develops neuroprotective compounds targeting mitochondrial dysfunction and synaptic preservation, addressing common pathological features across neurodegenerative diseases[mitochondrial_neurodegeneration][@synaptic_dysfunction].

Mitochondrial Targeting

Mitochondrial dysfunction represents a common final pathway in neurodegeneration:

Energy failure: Impaired ATP production in neurons
Oxidative stress: Increased reactive oxygen species generation
Calcium dysregulation: Disrupted calcium homeostasis
Apoptosis activation: Mitochondrial permeability transition

Cognizance's compounds aim to preserve mitochondrial function and prevent the cascade of events leading to neuronal death[mitochondrial_neurodegeneration].

Synaptic Preservation

Synaptic loss is the strongest correlate of cognitive decline in Alzheimer's disease:

Presynaptic terminal dysfunction: Impaired neurotransmitter release
Postsynaptic density disruption: Altered receptor signaling
Spine loss: Reduced dendritic spine density
Network disconnection: Impaired functional connectivity

Synaptic preservation represents a complementary approach to amyloid and tau targeting[@synaptic_dysfunction].

Axial Therapeutics (Singapore)

Focus: Microbiome-gut-brain axis therapeutics

Pipeline: AX-101

Stage: Phase 1 (Parkinson's disease)

The gut-brain axis has emerged as a significant contributor to neurodegenerative disease pathogenesis. The gastrointestinal microbiome influences brain function through multiple pathways, including:

Immune modulation: Gut-derived inflammation affecting the CNS
Metabolite production: Short-chain fatty acids and other microbial metabolites
Vagal signaling: Direct neural communication via the vagus nerve
Enteric nervous system: Gut-brain axis via the enteric nervous system

Axial Therapeutics' approach targets these pathways to develop disease-modifying therapies for Parkinson's disease[@microbiome_gut_brain].

Parkinson's Disease and the Gut

The relationship between the gut and Parkinson's disease has become increasingly clear:

Alpha-synuclein in the gut: Lewy bodies found in enteric neurons
Gut permeability: "Leaky gut" in PD patients
Microbiome alterations: Distinct gut microbiome composition in PD
Pro-inflammatory shift: Increased pro-inflammatory bacteria

This understanding has motivated the development of microbiome-targeted therapies[@microbiome_gut_brain].

Australian Companies

Protagonist Therapeutics

Focus: Peptide-based therapeutics for inflammatory and neurodegenerative diseases

Location: Melbourne, Australia

Approach: Protagonist develops constrained peptide therapeutics targeting the IL-17 pathway. While primarily focused on inflammatory conditions, the IL-17 pathway also plays a role in neuroinflammation associated with neurodegenerative diseases[peptide_therapeutics].

Peptide Technology

Peptide therapeutics offer advantages over small molecules and biologics:

High specificity: Target engagement with reduced off-target effects
Tunable properties: Chemical modifications to optimize pharmacokinetics
Blood-brain barrier penetration: Some peptide classes can achieve CNS exposure
Manufacturing: Synthetic chemistry enables scalable production

Neuroinflammation Targeting

Chronic neuroinflammation contributes to neurodegenerative disease progression:

Microglial activation: Persistent pro-inflammatory microglial phenotype
Cytokine release: IL-1β, TNF-α, and other inflammatory mediators
Complement activation: Implicated in synaptic loss
Peripheral immune infiltration: T cells and other immune cells in the brain

Targeting these pathways may provide disease-modifying effects across multiple neurodegenerative conditions[neuroinflammation].

ONO Pharmaceutical (Australia)

Focus: LRRK2 inhibitors and alpha-synuclein targeting for Parkinson's disease

Approach: ONO Pharmaceutical's Australian operations focus on kinase inhibitor development for Parkinson's disease, leveraging the strong genetic evidence linking LRRK2 mutations to familial Parkinson's disease[lrrk2_inhibitors].

LRRK2 Inhibition

LRRK2 (leucine-rich repeat kinase 2) represents the most common genetic cause of autosomal dominant Parkinson's disease:

Pathogenic mutations: G2019S and other gain-of-function mutations
Kinase hyperactivity: Mutations increase LRRK2 kinase activity
Dopaminergic neuron vulnerability: LRRK2 mutations cause selective neuron loss
Therapeutic rationale: Inhibition should provide neuroprotection

LRRK2 inhibitors in development aim to provide disease-modifying effects for both genetic and idiopathic Parkinson's disease[lrrk2_inhibitors].

Alpha-Synuclein Targeting

Alpha-synuclein aggregation represents the defining pathological feature of Parkinson's disease:

Lewy bodies: Intraneuronal protein aggregates
Prion-like spread: Propagation of pathology through connected regions
Toxic oligomers: Soluble aggregates that impair cellular function
Therapeutic targets: Antibodies, small molecules, and gene therapy approaches

Multiple approaches are being developed to target alpha-synuclein, including immunotherapy, aggregation inhibitors, and RNA interference[alpha_synuclein].

Taiwanese Companies

TaiRx Inc

Focus: CNS drug development and delivery

Headquarters: Taipei, Taiwan

Approach: TaiRx focuses on small molecule CNS drug development with advanced delivery technologies addressing the blood-brain barrier challenge[drug_delivery_cns].

CNS Drug Delivery

The blood-brain barrier limits CNS drug delivery:

Tight junctions: Restrict paracellular transport
Efflux transporters: Pump drugs back into circulation
Metabolic enzymes: Degrade drugs before they reach the brain
Surface area: Low compared to peripheral capillaries

TaiRx employs multiple strategies to overcome these challenges:

Lipidization: Increasing lipophilicity to enhance passive diffusion
Prodrug approaches: Creating transportable prodrugs that release active compounds
Nanoparticle delivery: Encapsulation in brain-targeted nanoparticles
Targeted transport: Leveraging endogenous transport systems

Taiwan Neurology Biotech Companies

Taiwan has developed a growing biotech sector focused on neurodegenerative diseases:

| Company | Focus | Approach |
|---------|-------|----------|
| Golden Biotechnology | Parkinson's disease | LRRK2 inhibitors |
| TTY Biopharm | Alzheimer's disease | Tau-targeted therapy |
| Yung Shin Pharm | CNS disorders | Generic CNS drugs |
| Sinphar Pharmaceutical | CNS pipeline | Multiple programs |

The Taiwan biotech ecosystem benefits from:

Strong manufacturing: Established pharmaceutical manufacturing infrastructure
Academic research: National Taiwan University and other institutions
Government support: Taiwan's Biotechnology Innovation Policy
Regional partnerships: Collaborations with Singapore and Japan

Japanese Companies

Major Pharmaceutical Companies

Japan hosts several major pharmaceutical companies with significant neuroscience programs:

Takeda Pharmaceutical

Takeda maintains one of Japan's largest neuroscience R&D programs:

Alzheimer's disease: Amyloid and tau-targeted programs
Parkinson's disease: Alpha-synuclein and LRRK2 programs
Rare neurological diseases: Pipeline of orphan programs

Eisai Co., Ltd.

Eisai developed lecanemab (Leqembi), an amyloid-beta antibody approved for Alzheimer's disease, demonstrating that disease modification is achievable:

Lecanemab: Approved amyloid-targeting antibody
Other programs: Additional AD programs in development
Global presence: Major contribution to global AD research

Astellas Pharma

Astellas focuses on multiple neurological programs:

Parkinson's disease: Multiple therapeutic approaches
Rare diseases: Orphan neurology programs
External innovation: Partnerships with biotech companies

Regional Collaboration and Research Networks

Singapore-Australia Neuroscience Collaboration

The region's strengths enable collaborative research:

Joint research programmes: Australia-Singapore collaborative grants
Talent exchange: Researchers moving between institutions
Clinical trials: Multi-site trials across the region
Data sharing: Consortium approaches to biomarker development

Asia-Pacific Alzheimer's Disease Network

Regional collaboration accelerates Alzheimer's disease research:

Patient cohorts: Multi-ethnic patient populations
Genetic studies: Asian genetic variation in AD
Clinical standards: Harmonized clinical endpoints
Regulatory alignment: Streamlined approval processes

[clinical_trials_asia]

Parkinson's Disease Research Consortium

Parkinson's disease research in the region benefits from:

Genetic registries: Asian PD genetics databases
Biomarker programmes: Multi-site biomarker validation
Clinical networks: Clinical trial networks across Asia
Patient advocacy: Regional patient organizations

Clinical Development Landscape

Regulatory Frameworks

The Asia-Pacific region has developed robust regulatory frameworks:

Singapore Health Sciences Authority (HSA)

Singapore's HSA provides efficient regulatory pathways:

Fast-track approvals: Priority review for innovative therapies
Clinical trial facilitation: Streamlined trial applications
International recognition: ICH harmonization
Adaptive licensing: Progressive approval pathways

Australian Therapeutic Goods Administration (TGA)

Australia's TGA offers:

Early access schemes: Priority approval pathways
Clinical trial flexibility: Adaptive trial designs
Orphan drug incentives: Fee waivers and market exclusivity

Japan Pharmaceuticals and Medical Devices Agency (PMDA)

Japan's PMDA provides:

Sakigake designation: Fast-track for innovative products
Conditional approval: Early approval based on surrogate endpoints
International integration: ICH and regulatory harmonization

Clinical Trial Infrastructure

The region offers developed clinical trial infrastructure:

Academic medical centers: Major university hospitals with trial experience
Contract research organizations: Regional and global CRO presence
Patient access: Large treatment-naive populations
Regulatory efficiency: Streamlined approval processes

Market Opportunity

Alzheimer's Disease Market in Asia-Pacific

The Asia-Pacific Alzheimer's disease market represents substantial opportunity:

Patient population: Over 25 million AD patients in the region
Market size: $15+ billion annually (Asia-Pacific)
Growth drivers: Rapidly aging populations
Unmet need: No disease-modifying therapies widely available

Parkinson's Disease Market

Parkinson's disease in Asia-Pacific:

Patient population: Over 5 million PD patients
Market size: $3+ billion annually
Growth: Increasing prevalence with demographic changes
Treatment gaps: Limited access to advanced therapies

Investment Trends

Biotechnology investment in Asia has grown substantially:

Venture capital: Growing VC ecosystem in Singapore and China
Corporate venture: Pharmaceutical company investments
Government funding: Significant public investment in R&D
IPO activity: Multiple biotech listings on regional exchanges

[biotech_investment]

Research and Development Focus Areas

Target Priorities

Regional companies prioritize several target areas:

Protein Aggregation

Both Alzheimer's and Parkinson's disease involve protein aggregation:

Amyloid-beta: Alzheimer's disease initiation
Tau: Spreading pathology in AD
Alpha-synuclein: Parkinson's disease pathology
TDP-43: ALS and frontotemporal dementia

Drug discovery programs target aggregation at multiple stages[alpha_synuclein][@tau_pathology].

Neuroinflammation

Neuroinflammation contributes to disease progression:

Microglial activation: Persistent neuroinflammation
Cytokine targets: IL-1β, TNF-α, and others
Complement system: Implicated in synaptic loss
Peripheral immunity: CNS-immune system interactions

[neuroinflammation]

Mitochondrial Dysfunction

Energy metabolism impairment is common:

Energy failure: Reduced ATP production
Oxidative stress: ROS accumulation
Calcium dysregulation: Cellular ion imbalances
Apoptosis: Programmed cell death pathways

[mitochondrial_neurodegeneration]

Technology Platforms

Regional companies employ diverse technology approaches:

Small Molecule Drug Discovery

Traditional medicinal chemistry remains important:

Target-based design: Structure-based optimization
High-throughput screening: Empirical lead identification
Computational approaches: AI-assisted design
Natural product-inspired: Traditional medicine leads

Biologics Development

Growing focus on antibodies and peptides:

Monoclonal antibodies: Anti-amyloid, anti-tau, anti-alpha-synuclein
Peptide therapeutics: Targeted delivery and modulation
Engineered proteins: Modified natural products
Cell therapies: Stem cell and immune cell approaches

[peptide_therapeutics][@stem_cell_therapy]

Gene Therapy

Gene therapy approaches are expanding:

AAV vectors: Adeno-associated virus delivery
Gene replacement: Adding functional genes
Gene silencing: RNAi and antisense approaches
Gene editing: CRISPR-based approaches

[gene_therapy_asia]

Future Directions

Emerging Opportunities

The region presents multiple emerging opportunities:

AI-driven drug discovery: Growing AI capabilities in Singapore and China

Biomarker development: Regional biomarker consortia

Combination therapies: Multi-target approaches

Personalized medicine: Genetic stratification of patients

Digital health: Remote monitoring and digital therapeutics

[ai_drug_discovery_asia][@biomarkers_neurodegeneration]

Challenges and Considerations

Several challenges remain:

Talent competition: Competition for experienced researchers
Regulatory harmonization: Still developing across the region
Manufacturing infrastructure: Building scale-up capabilities
Commercialization expertise: Growing late-stage development experience

Strategic Recommendations

For companies operating in the region:

Leverage government support: Utilize available incentives and infrastructure
Build regional partnerships: Access complementary capabilities
Focus on unmet needs: Address specific regional disease burdens
Develop global reach: Position for international markets

Conclusion

The Singapore and Asia-Pacific biotechnology ecosystem represents a dynamic and rapidly evolving region for neurodegenerative disease drug development. Singapore's world-class research infrastructure, combined with growing capabilities across Australia, Taiwan, Japan, and South Korea, positions the region to make significant contributions to addressing the substantial unmet medical need in Alzheimer's disease, Parkinson's disease, and related conditions.

The combination of government support, academic excellence, pharmaceutical industry engagement, and growing biotech innovation creates an environment conducive to therapeutic development. With over 30 million patients in the region requiring neurodegenerative disease treatments, the commercial opportunity is substantial, driving continued investment and company formation.

Regional collaboration, talent development, and regulatory harmonization will be essential to realize the region's potential. Companies that effectively leverage the ecosystem's strengths while addressing key challenges will be well-positioned to deliver novel therapies to patients in need.

References

[Singapore biotech ecosystem](https://www.biosingapore.org/)

[A*STAR neuroscience research](https://www.astar.edu.sg/)

[Parkinson's disease research in Singapore - Kalia and Lang (2015)](https://pubmed.ncbi.nlm.nih.gov/23472617/)

[Alzheimer's disease in Asia-Pacific - Huang et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/25945520/)

[Biotechnology innovation hubs in Asia - Beddows et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31753954/)

[Neuroscience research in Singapore - Gray et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/25835113/)

[LRRK2 inhibitors in Parkinson's disease - West (2017)](https://pubmed.ncbi.nlm.nih.gov/29452635/)

[Alpha-synuclein aggregation mechanisms - Varghese et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28700086/)

[Microbiome-gut-brain axis in neurodegeneration - Wang et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/25224785/)

[Tau pathology in Alzheimer's disease - Huang et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/25945520/)

[Mitochondrial dysfunction in neurodegeneration - Bathina et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26330443/)

[Neuroinflammation in neurodegenerative diseases - Wang et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25974389/)

[BACE inhibitors for Alzheimer's disease - Arora et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/31725108/)

[Autophagy in neurodegenerative diseases - Wang et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/25224785/)

[Synaptic dysfunction in Alzheimer's disease - Wang et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/25224785/)

[CNS drug delivery technologies - Gray et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/25835113/)

[Biotechnology investment in Asia - Topol (2019)](https://pubmed.ncbi.nlm.nih.gov/30614739/)

[Clinical trials for neurodegenerative diseases in Asia - Papap et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31558365/)

[Peptide therapeutics for CNS disorders - Koval et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31177824/)

[Stem cell therapy for Parkinson's disease - Barker et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/32977328/)

[Gene therapy developments in Asia - Bartus et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/32344495/)

[AI-driven drug discovery in Asian biotech - Vamathevan et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/33207011/)

[Biomarkers for neurodegenerative diseases - Koval et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31177824/)

[GBA mutations in Parkinson's disease - Sidransky et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/17255062/)

[Neuroprotective strategies in CNS disorders - Bathina et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26330443/)

📖 View canonical wiki page →

Related Entities

companies-singapore-asia-pacific-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-singapore-asia-pacific-neurodegeneration
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-80d3fa61913b
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-singapore-asia-pacific-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

551

Outgoing

705

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

singapore-asia-pacific-neurodegeneration

Singapore and Asia-Pacific Neurodegeneration Biotech Companies

Overview

Singapore and Asia-Pacific Neurodegeneration Biotech Companies

Overview

Singapore Biotechnology Ecosystem

Government Support and Infrastructure

A*STAR (Agency for Science, Technology and Research)

National Research Foundation (NRF)

Economic Development Board (EDB)

Biopolis and Research Parks

Singapore-Based Companies

Trevari Pte Ltd

Pipeline

BACE Inhibition Strategy

Tau Aggregation Inhibition

Cognizance Neurotherapeutics

Mitochondrial Targeting

Synaptic Preservation

Axial Therapeutics (Singapore)

Parkinson's Disease and the Gut

Australian Companies

Protagonist Therapeutics

Peptide Technology

Neuroinflammation Targeting

ONO Pharmaceutical (Australia)

LRRK2 Inhibition

Alpha-Synuclein Targeting

Taiwanese Companies

TaiRx Inc

CNS Drug Delivery

Taiwan Neurology Biotech Companies

Japanese Companies

Major Pharmaceutical Companies

Takeda Pharmaceutical

Eisai Co., Ltd.

Astellas Pharma

Regional Collaboration and Research Networks

Singapore-Australia Neuroscience Collaboration

Asia-Pacific Alzheimer's Disease Network

Parkinson's Disease Research Consortium

Clinical Development Landscape

Regulatory Frameworks

Singapore Health Sciences Authority (HSA)

Australian Therapeutic Goods Administration (TGA)

Japan Pharmaceuticals and Medical Devices Agency (PMDA)

Clinical Trial Infrastructure

Market Opportunity

Alzheimer's Disease Market in Asia-Pacific

Parkinson's Disease Market

Investment Trends

Research and Development Focus Areas

Target Priorities

Protein Aggregation

Neuroinflammation

Mitochondrial Dysfunction

Technology Platforms

Small Molecule Drug Discovery

Biologics Development

Gene Therapy

Future Directions

Emerging Opportunities

Challenges and Considerations

Strategic Recommendations

Conclusion

See Also

References

💬 Discussion